Full length is a starting point.
The therapeutic goal is useful protein function, not simply a longer chain. Correct amino-acid incorporation, expression level, stability and activity need to be assessed.
THE SCIENCE OF CONTINUATION
From genetic instruction
to working protein.
DNA stores the instructions for making proteins. An mRNA working copy is read by the ribosome in three-letter codons. tRNAs connect those codons to amino acids, allowing a protein chain to grow. At the normal end of the message, release factors recognise a stop signal.
THE MOLECULAR ADAPTOR
One RNA strand. A highly organised fold.
A tRNA is a single RNA molecule with intramolecularly paired stems and connecting loops. Its folded structure brings an amino-acid-carrying end and a codon-recognising region into the geometry needed for translation. It is not a DNA double helix.
Normal translation
A ribosome reads mRNA in three-letter codons. Aminoacyl-tRNAs deliver amino acids; the growing chain is extended until release factors recognise a normal stop.
The highlighted CAG is a sense codon. The ribosome moves along the message from 5′ to 3′.
ONE MUTATION. TWO CONNECTED FAILURES.
The protein can be cut short. The message can also be lost.
A nonsense mutation creates an early UAA, UAG or UGA stop. Premature termination can reduce useful protein output. Nonsense-mediated decay can additionally reduce the transcript, although the extent depends on sequence, transcript structure and cellular context.
There must be a message to read.
Message availability and readthrough need to be considered together. A candidate’s success in one transcript or cell context does not establish its performance in another.
THE SUPPRESSOR-tRNA IDEA
Read the premature stop as an opportunity to continue.
An engineered suppressor tRNA can recognise a selected stop codon and deliver an amino acid. If it competes successfully with termination, translation can continue downstream towards a full-length protein. This is a therapeutic possibility that must be tested for activity, specificity and function.
Works during translation
A suppressor tRNA acts while the ribosome reads mRNA. The intended mechanism does not edit the DNA sequence. Delivery and expression format determine how long the intervention persists.
Uses the cell’s message
The aim is to recover protein production from a transcript made by the cell. There must be enough relevant transcript available for that strategy to work.
Starts with a specific biological context
Codon recognition, amino-acid identity, tRNA function and the environment around the premature stop all matter. A candidate must be tested in a relevant system.
Builds transferable knowledge
Different genes can share a premature-stop mechanism. Evidence and methods may inform additional programmes, while disease biology, delivery and safety still require programme-specific work.
FOUR CONDITIONS, CONSIDERED TOGETHER
A successful design has to work inside biology.
Can the tRNA carry its intended amino acid?
A tRNA must be recognised and charged by an appropriate aminoacyl-tRNA synthetase. Recognition of a stop codon alone is not sufficient.
Can translation continue at the selected stop?
The suppressor tRNA competes with the machinery that normally ends translation. The local sequence and the state of the ribosome matter.
Is there enough mRNA left to read?
Nonsense-mediated decay can reduce the available transcript. Its effect varies with the gene, transcript architecture and cellular context.
Can the candidate reach the right cells?
A promising molecular design still needs a credible route to the relevant tissue and an effective intracellular exposure.
NORMAL-STOP FIDELITY
Premature and native stops use the same stop-codon vocabulary. Selectivity cannot be assumed from the word “premature”. Normal-stop readthrough and broader cellular effects require measurement alongside target activity.
PUBLIC SCIENTIFIC FOUNDATION
Research you can examine.
Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations
Nature Communications · 2024 · 15:2957. Nikhil Bharti and Leonardo Santos contributed equally. This published academic work is a scientific foundation, not validation of KritRNA’s developing platform.
Read the paper ↗A single-chain tRNA structure.
The hero uses a rendering of the public 1EHZ yeast phenylalanine tRNA structure when reference data are available. It is a reference molecule, not a KritRNA therapeutic candidate.
Examine the reference ↗The science shapes
what we build.
KritRNA is developing a connected candidate-design and translation-systems platform to turn these biological questions into informed experimental choices.
Explore the platform ↗